Gut microbiota control gut permeability through GLP-2.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Curcumin and Tetrahydrocurcumin as Multi-Organ Modulators of the Adipose Tissue-Gut-Liver Axis: Mechanistic Insights, Therapeutic Potential, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2025
   Review
2. Molecular interactions between the intestinal microbiota and the host.Molecular microbiology · 2022
   Review
3. Gut microbiota as a target for prevention and treatment of type 2 diabetes: Mechanisms and dietary natural products.World journal of diabetes · 2021
   Review
4. Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications.Frontiers in pharmacology · 2021
   Review
5. Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2019
   Review
6. Intestinal Sensing by Gut Microbiota: Targeting Gut Peptides.Frontiers in endocrinology · 2019
   Review
7. Purified Phlorizin fromMolecules (Basel, Switzerland) · 2018
   Article

Corrections and comments

• Comment on
  Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.